Suppr超能文献

卡托普利试验在原发性醛固酮增多症中的诊断价值。

Diagnostic value of the post-captopril test in primary aldosteronism.

作者信息

Castro Oscar L, Yu Xichun, Kem David C

机构信息

Department of Medicine, University of Oklahoma, and Veterans Administration Medical Center, Oklahoma City, Okla, USA.

出版信息

Hypertension. 2002 Apr;39(4):935-8. doi: 10.1161/01.hyp.0000014324.68506.ca.

Abstract

Primary aldosteronism is a disorder with hypertension, hypokalemia, increased plasma aldosterone, and suppressed renin activity. A random plasma aldosterone/renin activity (PA/PRA) >65 (conventional units ratio [CUR] >30) has been proposed as a screening test. We have retrospectively determined the value of the post-captopril plasma aldosterone/renin activity (CAPT PA/PRA) test for the diagnosis of patients with primary aldosteronism whose PA/PRA was <65. We considered the CAPT PA/PRA test to be positive for primary aldosteronism if either the plasma aldosterone concentration did not drop below 0.33 nmol/L (12 ng/dL) or the ratio was >26 (CUR >12). We found 6 patients with a random PA/PRA of 21 to 60 (CUR 10 to 28), yet with an abnormal post-captopril test criteria for primary aldosteronism. Five had an abnormal saline suppression test, and all 6 were confirmed by a combination of diagnostic localization with computerized axial tomography, iodocholesterol scan, adrenal venous sampling, and/or surgery. Four had idiopathic adrenal hyperplasia, and 2 had an aldosterone-producing adenoma. One other patient had an abnormal random plasma aldosterone/renin activity ratio of 99 (CUR 46), a negative saline infusion study, and was determined to have essential hypertension. In summary, the CAPT PA/PRA, but not the random PA/PRA, correctly diagnosed 6 patients with primary aldosteronism in our institution. An additional patient with essential hypertension was incorrectly diagnosed as having primary aldosteronism by the PA/PRA test. We conclude that the simple addition of 25 mg of captopril, taken orally 2 hours before sampling, enhances the accuracy for diagnosing patients with primary aldosteronism.

摘要

原发性醛固酮增多症是一种伴有高血压、低钾血症、血浆醛固酮升高及肾素活性受抑制的疾病。随机血浆醛固酮/肾素活性(PA/PRA)>65(传统单位比值[CUR]>30)已被提议作为一项筛查试验。我们回顾性地确定了卡托普利激发试验后血浆醛固酮/肾素活性(CAPT PA/PRA)试验对PA/PRA<65的原发性醛固酮增多症患者诊断的价值。如果血浆醛固酮浓度未降至0.33 nmol/L(12 ng/dL)以下或比值>26(CUR>12),我们认为CAPT PA/PRA试验对原发性醛固酮增多症呈阳性。我们发现6例患者随机PA/PRA为21至60(CUR为10至28),但其卡托普利激发试验标准对原发性醛固酮增多症异常。5例患者生理盐水抑制试验异常,所有6例均通过计算机断层扫描、碘胆固醇扫描、肾上腺静脉采血和/或手术等诊断定位方法联合确诊。4例为特发性肾上腺增生,2例为醛固酮瘤。另有1例患者随机血浆醛固酮/肾素活性比值异常,为99(CUR为46),生理盐水输注试验阴性,诊断为原发性高血压。总之,在我们机构中,CAPT PA/PRA而非随机PA/PRA正确诊断了6例原发性醛固酮增多症患者。1例原发性高血压患者被PA/PRA试验错误诊断为原发性醛固酮增多症。我们得出结论,在采样前2小时口服25 mg卡托普利这一简单方法可提高原发性醛固酮增多症患者的诊断准确性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验